Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
Under a Creative Commons license
open access
Abbreviations
ANOVA
analysis of variance
ATF-1
activating transcription factor-1
CCL-2
chemokine ligand 2
CCL-8
chemokine ligand 8
CCL-18
chemokine ligand 18
CCR-1
chemokine receptor 1
CRBN
cereblon
CRE
cAMP responsive element
CREB
cAMP responsive element binding protein
CXCL-5
CXC cytokine ligand 5
DCs
dendritic cells
DMSO
dimethyl sulfoxide
EC50
half-maximal effective concentration
ED50
half-maximal effective drug concentration
ELISA
enzyme-linked immunosorbent assay
Epac
exchange proteins activated by cAMP
FP
fluorescence polarization
HEL
hen egg lysozyme
IC50
half-maximal inhibitory concentration
Ig
immunoglobulin
IL
interleukin
IP-10
interferon-inducible protein 1
LPS
lipopolysaccharide
MCP-1
monocyte chemoattractant protein 1
MCP-2
monocyte chemoattractant protein 2
MHC
major histocompatibility complex
MIP-1αR
macrophage inflammatory protein 1-α receptor
MIP-4
macrophage inflammatory protein-4
MX1
myxovirus resistant 1
NF-κB
nuclear factor-kappa B
NK
natural killer
OVA
ovalbumin
PBMCs
peripheral blood mononuclear cells
PBS
phosphate-buffered saline
PDE4
phosphodiesterase 4
PKA
protein kinase A
PsA
psoriatic arthritis
SOCS-3
suppressor of cytokine signaling 3
TLR
toll-like receptor
TNF
tumor necrosis factor
Keywords
Apremilast
Phosphodiesterase inhibitor
Preclinical drug evaluation
Psoriasis
Psoriatic arthritis
Spondyloarthropathies
Cited by (0)
Copyright © 2014 The Authors. Published by Elsevier Inc.